幽门螺杆菌对利福布汀耐药性的 7 年回顾
Helicobacter pylori resistance to rifabutin in the last 7 years.
机构信息
Division of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
出版信息
Antimicrob Agents Chemother. 2011 Nov;55(11):5374-5. doi: 10.1128/AAC.05437-11. Epub 2011 Sep 6.
Abstract
A low rate of resistance (0.24%) to rifabutin was noted in Helicobacter pylori strains isolated from 414 Japanese patients. The only rifabutin-resistant strain detected showed a point mutation in the rpoB gene and was isolated from a patient with a history of rifampin treatment for pulmonary tuberculosis.
摘要
从 414 例日本患者中分离的幽门螺杆菌菌株对利福布汀的耐药率较低（0.24%）。唯一检测到的耐利福布汀菌株显示 rpoB 基因突变，该菌株从一名曾因肺结核接受利福平治疗的患者中分离。
相似文献
1
Helicobacter pylori resistance to rifabutin in the last 7 years.幽门螺杆菌对利福布汀耐药性的 7 年回顾
Antimicrob Agents Chemother. 2011 Nov;55(11):5374-5. doi: 10.1128/AAC.05437-11. Epub 2011 Sep 6.
2
Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany.德国耐利福平临床幽门螺杆菌分离株的特征分析
J Antimicrob Chemother. 2007 May;59(5):874-9. doi: 10.1093/jac/dkm039. Epub 2007 Mar 9.
3
Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori.既往利福平给药情况决定幽门螺杆菌对利福布汀的耐药性。
Digestion. 2009;79(1):1-4. doi: 10.1159/000191204. Epub 2009 Jan 14.
4
Molecular characterization of Helicobacter pylori resistance to rifamycins.幽门螺杆菌对利福霉素耐药性的分子特征。
Helicobacter. 2018 Feb;23(1). doi: 10.1111/hel.12451. Epub 2017 Nov 23.
5
Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.尼泊尔幽门螺杆菌左氧氟沙星耐药性的出现及新的基因突变
BMC Microbiol. 2016 Nov 4;16(1):256. doi: 10.1186/s12866-016-0873-6.
6
Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan.台湾地区难治性幽门螺杆菌感染中利福布汀耐药的分子特征。
Int J Infect Dis. 2024 Jan;138:25-28. doi: 10.1016/j.ijid.2023.11.001. Epub 2023 Nov 11.
7
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.埃索美拉唑、莫西沙星和利福布汀一周一次的三联疗法用于根除对甲硝唑和克拉霉素均耐药的持续性幽门螺杆菌。
Helicobacter. 2008 Feb;13(1):69-74. doi: 10.1111/j.1523-5378.2007.00588.x.
8
Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.基于培养的选择疗法用于治疗先前对幽门螺杆菌感染治疗无反应的患者。
Clin Gastroenterol Hepatol. 2013 May;11(5):507-10. doi: 10.1016/j.cgh.2012.12.007. Epub 2012 Dec 23.
9
Rifamycin use for treatment of infection: a review of recent data.利福霉素治疗 感染：近期数据回顾。
Future Microbiol. 2020 Aug;15:1185-1196. doi: 10.2217/fmb-2020-0084.
10
Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin.基于利福布汀的三联疗法用于根除对替硝唑和克拉霉素原发性及继发性耐药的幽门螺杆菌。
Dig Liver Dis. 2005 Jan;37(1):33-8. doi: 10.1016/j.dld.2004.09.008.
引用本文的文献
1
Antibiotic Resistance of : Mechanisms and Clinical Implications.耐药性的抗生素 : 机制和临床意义。
J Korean Med Sci. 2024 Jan 29;39(4):e44. doi: 10.3346/jkms.2024.39.e44.
2
Exploring Alternative Treatment Choices for Multidrug-Resistant Clinical Strains of in Mongolia.探索蒙古耐多药临床菌株的替代治疗选择。
Microorganisms. 2023 Nov 24;11(12):2852. doi: 10.3390/microorganisms11122852.
3
Development of apigenin loaded gastroretentive microsponge for the targeting of .用于靶向递送的载芹菜素胃滞留微球的研制
Saudi Pharm J. 2023 May;31(5):659-668. doi: 10.1016/j.jsps.2023.03.006. Epub 2023 Mar 13.
4
Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Infections.抗生素耐药性的分子机制及感染的新型治疗策略
Trop Med Infect Dis. 2023 Mar 11;8(3):163. doi: 10.3390/tropicalmed8030163.
5
Rifabutin as salvage therapy for eradication: Cornerstones and novelties.利福布汀作为补救治疗根除的选择：要点和新进展。
World J Gastroenterol. 2022 Dec 7;28(45):6356-6362. doi: 10.3748/wjg.v28.i45.6356.
6
Clinical Implications of Antibiotic Resistance in Italy: A Review of the Literature.意大利抗生素耐药性的临床影响：文献综述
Antibiotics (Basel). 2022 Oct 21;11(10):1452. doi: 10.3390/antibiotics11101452.
7
Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.低剂量利福布汀为基础的 7 天三联疗法作为三线或更后线幽门螺杆菌根除方案的疗效和安全性。
Helicobacter. 2022 Aug;27(4):e12900. doi: 10.1111/hel.12900. Epub 2022 May 29.
8
Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.幽门螺杆菌感染、实验室诊断及抗菌耐药性：临床相关性视角。
Clin Microbiol Rev. 2022 Sep 21;35(3):e0025821. doi: 10.1128/cmr.00258-21. Epub 2022 Apr 11.
9
Sitafloxacin for Third-Line Eradication: A Systematic Review.西他沙星用于三线根除治疗：一项系统评价
J Clin Med. 2021 Jun 20;10(12):2722. doi: 10.3390/jcm10122722.
10
Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.幽门螺杆菌感染和抗生素耐药性 - 从生物学到临床意义。
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):613-629. doi: 10.1038/s41575-021-00449-x. Epub 2021 May 17.
本文引用的文献
1
Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication.幽门螺杆菌根除失败后阿莫西林耐药性增强。
Antimicrob Agents Chemother. 2011 Jun;55(6):3012-4. doi: 10.1128/AAC.00188-11. Epub 2011 Apr 12.
2
Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori.外排泵对幽门螺杆菌克拉霉素耐药性的贡献。
J Gastroenterol Hepatol. 2010 May;25 Suppl 1:S75-9. doi: 10.1111/j.1440-1746.2009.06220.x.
3
Helicobacter pylori eradication therapy.幽门螺杆菌根除治疗。
Future Microbiol. 2010 Apr;5(4):639-48. doi: 10.2217/fmb.10.25.
4
Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication.基于喹诺酮的三线疗法根除幽门螺杆菌。
J Clin Biochem Nutr. 2009 Mar;44(2):119-24. doi: 10.3164/jcbn.08-220R. Epub 2009 Feb 28.
5
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.司帕沙星和加雷沙星可能克服携带gyrA基因突变的幽门螺杆菌的抗生素耐药性。
Antimicrob Agents Chemother. 2009 Apr;53(4):1720-1. doi: 10.1128/AAC.00049-09. Epub 2009 Feb 2.
6
Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori.既往利福平给药情况决定幽门螺杆菌对利福布汀的耐药性。
Digestion. 2009;79(1):1-4. doi: 10.1159/000191204. Epub 2009 Jan 14.
7
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.基于加替沙星的三联疗法作为根除幽门螺杆菌的三线治疗方案。
J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S167-70. doi: 10.1111/j.1440-1746.2008.05407.x.
8
A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori.
Digestion. 2007;76(3-4):215-20. doi: 10.1159/000112649. Epub 2007 Dec 21.
9
The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice.利福布汀三联疗法在临床实践中对幽门螺杆菌难以根除患者的有效性。
Aliment Pharmacol Ther. 2007 Dec;26(11-12):1537-42. doi: 10.1111/j.1365-2036.2007.03531.x. Epub 2007 Sep 28.
10
Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR.通过等位基因特异性PCR快速检测幽门螺杆菌gyrA中赋予对氟喹诺酮耐药性的点突变
J Clin Microbiol. 2007 Feb;45(2):303-5. doi: 10.1128/JCM.01997-06. Epub 2006 Nov 22.
Zotero 插件